Trial Profile
ABT 450 + ritonavir + peginterferon alfa-2a + ribavirin in treatment-naive patients with genotype 1 hepatitis C
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2011
Price :
$35
*
At a glance
- Drugs Paritaprevir (Primary) ; Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Ritonavir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 04 Apr 2011 New trial record
- 03 Apr 2011 Results presented at the 46th Annual Meeting of the European Association for the Study of the Liver.